221 related articles for article (PubMed ID: 32758289)
1. Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa.
Zhao L; Wang S; Li X; He X; Jian L
Antimicrob Resist Infect Control; 2020 Aug; 9(1):124. PubMed ID: 32758289
[TBL] [Abstract][Full Text] [Related]
2. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance.
Bruchmann S; Dötsch A; Nouri B; Chaberny IF; Häussler S
Antimicrob Agents Chemother; 2013 Mar; 57(3):1361-8. PubMed ID: 23274661
[TBL] [Abstract][Full Text] [Related]
3. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
Lei YC; Wang HB; Sun ZY; Shen ZY
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
[TBL] [Abstract][Full Text] [Related]
4. The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran.
Nouri R; Ahangarzadeh Rezaee M; Hasani A; Aghazadeh M; Asgharzadeh M
Braz J Microbiol; 2016; 47(4):925-930. PubMed ID: 27522930
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates.
Pasca MR; Dalla Valle C; De Jesus Lopes Ribeiro AL; Buroni S; Papaleo MC; Bazzini S; Udine C; Incandela ML; Daffara S; Fani R; Riccardi G; Marone P
Microb Drug Resist; 2012 Feb; 18(1):23-32. PubMed ID: 21797666
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial resistance and novel mutations detected in the gyrA and parC genes of Pseudomonas aeruginosa strains isolated from companion dogs.
Park Y; Oh J; Park S; Sum S; Song W; Chae J; Park H
BMC Vet Res; 2020 Apr; 16(1):111. PubMed ID: 32293442
[TBL] [Abstract][Full Text] [Related]
7. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
8. Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators.
Morero NR; Monti MR; Argaraña CE
Antimicrob Agents Chemother; 2011 Aug; 55(8):3668-76. PubMed ID: 21646492
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.
Lomovskaya O; Warren MS; Lee A; Galazzo J; Fronko R; Lee M; Blais J; Cho D; Chamberland S; Renau T; Leger R; Hecker S; Watkins W; Hoshino K; Ishida H; Lee VJ
Antimicrob Agents Chemother; 2001 Jan; 45(1):105-16. PubMed ID: 11120952
[TBL] [Abstract][Full Text] [Related]
10. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
12. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
Pasquali F; Manfreda G
Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
[TBL] [Abstract][Full Text] [Related]
13. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa.
Kriengkauykiat J; Porter E; Lomovskaya O; Wong-Beringer A
Antimicrob Agents Chemother; 2005 Feb; 49(2):565-70. PubMed ID: 15673734
[TBL] [Abstract][Full Text] [Related]
14. Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin.
Llanes C; Köhler T; Patry I; Dehecq B; van Delden C; Plésiat P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5676-84. PubMed ID: 21911574
[TBL] [Abstract][Full Text] [Related]
15. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P
J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
[TBL] [Abstract][Full Text] [Related]
16. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates.
Coban AY; Ekinci B; Durupinar B
Chemotherapy; 2004 Apr; 50(1):22-6. PubMed ID: 15084801
[TBL] [Abstract][Full Text] [Related]
17. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
Jeannot K; Elsen S; Köhler T; Attree I; van Delden C; Plésiat P
Antimicrob Agents Chemother; 2008 Jul; 52(7):2455-62. PubMed ID: 18474583
[TBL] [Abstract][Full Text] [Related]
18. Correlation between virulence genotype and fluoroquinolone resistance in carbapenem-resistant Pseudomonas aeruginosa.
Cho HH; Kwon KC; Kim S; Koo SH
Ann Lab Med; 2014 Jul; 34(4):286-92. PubMed ID: 24982833
[TBL] [Abstract][Full Text] [Related]
19. Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.
Cabot G; Zamorano L; Moyà B; Juan C; Navas A; Blázquez J; Oliver A
Antimicrob Agents Chemother; 2016 Jan; 60(3):1767-78. PubMed ID: 26729493
[TBL] [Abstract][Full Text] [Related]
20. Enhanced resistance to fluoroquinolones in laboratory-grown mutants & clinical isolates of Shigella due to synergism between efflux pump expression & mutations in quinolone resistance determining region.
Taneja N; Mishra A; Kumar A; Verma G; Sharma M
Indian J Med Res; 2015 Jan; 141(1):81-9. PubMed ID: 25857499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
